BIOLASE (BIOL) Competitors

Autonomix Medical has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Autonomix Medical's return on equity of -228.82% beat BIOLASE's return on equity.

Autonomix Medical presently has a consensus target price of $2.00, suggesting a potential upside of 401.25%. Given Autonomix Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Autonomix Medical is more favorable than BIOLASE.

In the previous week, Autonomix Medical had 2 more articles in the media than BIOLASE. MarketBeat recorded 2 mentions for Autonomix Medical and 0 mentions for BIOLASE. Autonomix Medical's average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score.

Autonomix Medical has a beta of -1.82, suggesting that its share price is 282% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 6.2% of Autonomix Medical shares are owned by insiders. Comparatively, 0.3% of BIOLASE shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Autonomix Medical has higher earnings, but lower revenue than BIOLASE. Autonomix Medical is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Pheton'saverage media sentiment score.

BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, meaning that its stock price is 440% more volatile than the broader market.

Pheton has lower revenue, but higher earnings than BIOLASE.

8.8% of BIOLASE shares are owned by institutional investors. 0.3% of BIOLASE shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pheton has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Pheton's return on equity of 0.00% beat BIOLASE's return on equity.

Given BIOLASE's higher possible upside, equities analysts plainly believe BIOLASE is more favorable than Pheton.

BIOLASE has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Profusa has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Profusa's return on equity of 0.00% beat BIOLASE's return on equity.

Given BIOLASE's higher possible upside, equities analysts plainly believe BIOLASE is more favorable than Profusa.

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 0.3% of BIOLASE shares are held by insiders. Comparatively, 11.4% of Profusa shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Profusa had 5 more articles in the media than BIOLASE. MarketBeat recorded 5 mentions for Profusa and 0 mentions for BIOLASE. Profusa's average media sentiment score of 0.22 beat BIOLASE's score of 0.00 indicating that Profusa is being referred to more favorably in the news media.

BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Profusa has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Bluejay Diagnostics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Bluejay Diagnostics' return on equity of -144.27% beat BIOLASE's return on equity.

Given BIOLASE's higher probable upside, analysts clearly believe BIOLASE is more favorable than Bluejay Diagnostics.

18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 0.1% of Bluejay Diagnostics shares are owned by company insiders. Comparatively, 0.3% of BIOLASE shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bluejay Diagnostics has higher earnings, but lower revenue than BIOLASE. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

In the previous week, Bluejay Diagnostics had 5 more articles in the media than BIOLASE. MarketBeat recorded 5 mentions for Bluejay Diagnostics and 0 mentions for BIOLASE. Bluejay Diagnostics' average media sentiment score of 1.18 beat BIOLASE's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media.

Bluejay Diagnostics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.